Citations

Showing 10 of 108083 citations.

Allowing Surgical Pathology Fellows to Release Preliminary Reports Increases Learner Independence and Satisfaction
Solanki, Malvika , Fritchie, Karen , Russell, Teresa E., Moen, Benjamin P., Maleszewski, Joseph J. , Hernandez, Loren P. Herrera , Boland, Jennifer M. , Solanki, Malvika H, Graham, Rondell P.

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 19, 2023 | Volume: 147 | Issue: 11 | Pages: 1320-1326

10.5858/arpa.2022-0223-oa | PMID 36656169 Get It

Context.— Progressive independence in medicine is critical to building confidence and decisiveness in trainees. However, this can be difficult to accomplish in the strict regulatory environment of pathology. Objective.— To pilot and adopt a process whereby surgical pathology fellows independently manage a subset of cases and release preliminary reports. Design.— Upon program approval, board-certified surgical pathology fellows were eligible for preliminary report sign-out at their discretion. Eligible cases were sent from outside institutions for confirmatory review. Preliminary reports were viewable in the electronic medical record. Safety measures were used to ensure timely release of final reports by attending pathologists. Results.— Fellows participating in the pilot (n = 4) released 59 preliminary reports out of 101 cases reviewed (58%), with 1 potentially significant discrepancy between preliminary and final report. Turnaround time was not affected. The process was endorsed by all participants and adopted as standard practice. During the first year, eligible fellows (n = 8) released 123 preliminary reports out of 1260 cases reviewed (9.8%). There were no major diagnostic discrepancies and no effects on turnaround time. The number of preliminary reports released by each fellow was variable (range, 2–48; median, 8), likely a reflection of both external factors (number of trainees on service, volume) and trainee-specific factors (confidence, efficiency). Conclusions.— Fellows showed good judgment when independently managing cases, with just 1 potentially significant discrepancy out of 182 cases (<1%). No patients were adversely impacted. Use of this process varied widely among fellows and may require closer monitoring and encouragement for fellows who are tentative about releasing preliminary reports.
Submucosal Necrotic Nodule of the Colon: An Enigmatic Entity Potentially Related to Anisakis Infection
Pyatibrat, Sergey , Arias, Hernán Darío Quiceno, Gil, Yolanda Rodrı́guez , Booth, Adam L. , Navarro, Itziar de la Peña , Garmendia-Irizar, Maddi, Lapointe, Jennifer R., Mobarki, Mousa , Nova‐Camacho, Luiz M. , Parini, Gina, Romio, Estefanía, Alayza, Alejandra Rosell, Pritt, Bobbi S. , Ruz‐Caracuel, Ignacio , Pritt, Bobbi S , González, Raul S. , Guerra, Laura

Mayo Clinic

Archives of Pathology & Laboratory Medicine | January 19, 2023 | Volume: 147 | Issue: 11 | Pages: 1315-1319

10.5858/arpa.2022-0267-oa | PMID 36656170 Get It

Context.— Discrete submucosal necrotic nodules may rarely manifest as colon polyps. Objective.— To characterize the clinical and pathologic features of this lesion, which has been under-studied in the literature. Design.— We conducted an international search to compile a series. For each potential case, photomicrographs were centrally reviewed to confirm the diagnosis. We gathered clinical and pathologic information on each confirmed case. Results.— The final cohort included 25 patients, with 23 having 1 lesion and 2 having several (31 lesions total). Mean patient age was 62 years; 13 patients (52%) were male. Symptoms were nonspecific, although 4 patients (16%) had blood in stool; 14 patients were asymptomatic. Patient history and medications appeared noncontributory. Most cases were located in the right colon (n = 18; 58%). Mean lesion size was 0.4 cm (range, 0.1–1.7 cm). Histology typically showed a centrally necrotic nodule with peripheral fibrosis, chronic inflammation, and sometimes palisading granulomatous inflammation. Percent necrosis ranged from 5% to 95% (average, 70%), and percent fibrosis ranged from 3% to 70% (average, 25%). In 3 cases, degenerated parasitic structures consistent with Anisakis could be seen on hematoxylin-eosin and trichrome special stain. No patient experienced disease recurrence. Conclusions.— Submucosal necrotic nodules can present as colon polyps. Most cases are unifocal, and patients do well on follow-up. At least some examples appear to be caused by Anisakis, implicating patient diet. Patients are often asymptomatic, and many cases show no histologic evidence of the causative agent.
Comparison of warfarin with direct oral anticoagulants for thromboembolic prophylaxis after catheter ablation of ventricular tachycardia
Deshmukh, Amrish , Gunda, Sampath , Siontis, Konstantinos C. , Ghannam, Michael , Liang, Jackson J. , Latchamsetty, Rakesh , Jongnarangsin, Krit, Morady, Fred, Bogun, Frank , Liang, Jackson , Deshmukh, Amrish

Mayo Clinic

Journal of Cardiovascular Electrophysiology | January 19, 2023 | Volume: 34 | Issue: 4 | Pages: 967-972

10.1111/jce.15827 | PMID 36655538 Get It

AbstractIntroductionThromboembolic events after catheter ablation of ventricular tachycardia (VT) can result in significant morbidity. Thromboembolic prophylaxis after catheter ablation can be achieved by the use of antiplatelet agents, vitamin K antagonists, or direct oral anticoagulants (DOACs). The relative safety and efficacy of these modes of prophylaxis are uncertain. We sought to compare the outcomes of patients who received warfarin or DOACs for thromboembolic prophylaxis after catheter ablation of VT.Methods and ResultsAnticoagulation with DOACS was started after left ventricular VT ablation in a series of 42 consecutive patients with structural heart disease (67 ± 11 years, 3 women, ejection fraction 32 ± 14%). Duration of hospital stay, bleeding episodes, and thromboembolic events were compared to a historic consecutive group of patients (n = 38, 65 ± 13 years, 14 women, ejection fraction 36 ± 13%) in whom anticoagulation with a formerly described protocol of heparin and vitamin K antagonist was used after VT ablation procedures. Hospital stay was significantly shorter in the group where DOACs were used as compared to vitamin K antagonists (3.3 ± 1.8 vs. 5.0 ± 2.5 days postablation; p = 0.001) without an increase of bleeding or thromboembolic events.ConclusionAnticoagulation with DOACs is safe and shortens hospital stay in patients with structural heart disease undergoing left ventricular VT ablation procedures.
Identification of Deep Cervical Fascial Layers During Anterior Cervical Spine Exposure
Archang, Maani M. , Tubbs, Shane, Janus, Jeffrey R. , Lee, Seung-Jin, Archang, Maani, Lee, Seung Jin , Riew, Kiehyun Daniel , Clifton, William

Mayo Clinic

Operative Neurosurgery | January 19, 2023 | Volume: 24 | Issue: 6 | Pages: e414-e420

10.1227/ons.0000000000000626 | PMID 36656028 Get It

BACKGROUND: Anterior approaches to the cervical spine are among the most common exposures by which neurosurgeons and orthopedic surgeons access the prevertebral space and ultimately the cervical disk and vertebral bodies. There is a paucity of literature describing the microanatomic fascial planes of the neck with respect to anterior cervical approaches. OBJECTIVE: To delineate the microanatomic connections of the cervical fascial planes pertinent to anterior cervical exposure. METHODS: Using a cadaveric model, original illustrations, the Visible Human Project, and an original surgical video, we demonstrate a stepwise method for identifying the correct planes for anterior cervical exposure. RESULTS: A step-by-step method for identifying the anterior cervical fascial planes intraoperatively is demonstrated. CONCLUSION: A comprehensive understanding of anterior cervical microsurgical anatomy is vital for performing a methodical yet efficient approach to the prevertebral space while minimizing retraction and iatrogenic injury to the surrounding neurovascular structures.
A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administration–Approved PD-1 and PD-L1 Inhibitors
Barham, Whitney , Hsu, Michelle A. , Liu, Xin , Harrington, Susan M. , Hirdler, Jacob B. , Gicobi, Joanina K. , Zhu, Xingxing , Zeng, Hu , Pavelko, Kevin D. , Yan, Yiyi , Hsu, Michelle, Mansfield, Aaron S , Dong, Haidong , Pavelko, Kevin D , Zeng, Hu , Zhu, Xingxing , Mansfield, Aaron S. , Dong, Haidong

Mayo Clinic

ImmunoHorizons | January 19, 2023 | Volume: 7 | Issue: 1 | Pages: 125-139

10.4049/immunohorizons.2200054 | PMID 36656137 Get It

Abstract Seven different anti–PD-1 and PD-L1 mAbs are now widely used in the United States to treat a variety of cancer types, but no clinical trials have compared them directly. Furthermore, because many of these Abs do not cross-react between mouse and human proteins, no preclinical models exist in which to consider these types of questions. Thus, we produced humanized PD-1 and PD-L1 mice in which the extracellular domains of both mouse PD-1 and PD-L1 were replaced with the corresponding human sequences. Using this new model, we sought to compare the strength of the immune response generated by Food and Drug Administration–approved Abs. To do this, we performed an in vivo T cell priming assay in which anti–PD-1/L1 therapies were given at the time of T cell priming against surrogate tumor Ag (OVA), followed by subsequent B16-OVA tumor challenge. Surprisingly, both control and Ab-treated mice formed an equally robust OVA-specific T cell response at the time of priming. Despite this, anti–PD-1/L1-treated mice exhibited significantly better tumor rejection versus controls, with avelumab generating the best protection. To determine what could be mediating this, we identified the increased production of CX3CR1+PD-1+CD8+ cytotoxic T cells in the avelumab-treated mice, the same phenotype of effector T cells known to increase in clinical responders to PD-1/L1 therapy. Thus, our model permits the direct comparison of Food and Drug Administration–approved anti–PD-1/L1 mAbs and further correlates successful tumor rejection with the level of CX3CR1+PD-1+CD8 + T cells, making this model a critical tool for optimizing and better utilizing anti–PD-1/L1 therapeutics.
Comparative Treatment Outcomes for Idiopathic Subglottic Stenosis: 5‐Year Update
Tierney, William S. , Huang, Li‐Ching , Chen, Sheau‐Chiann , Berry, Lynn D., Anderson, Catherine , Benninger, Michael S. , Blumin, Joel H. , Bryson, Paul C. , Castellanos, Paul F., Cohen, Seth M. , Crawley, Brianna K. , Dailey, Seth H. , Daniero, James J. , Alarcón, Alessandro de , Donovan, Donald T., Edell, Eric S. , Ekbom, Dale C. , Fink, Daniel S. , Franco, Ramon A. , Garrett, Catherine Gaelyn, Hoffman, Henry T. , Hogikyan, Norman D. , Howell, Rebecca J. , Johns, Michael M. , Kasperbauer, Jan L. , Khosla, Sid , Kinnard, Cheryl, Kupfer, Robbi A. , Langerman, Alexander , Lentz, Robert J. , Lorenz, Robert R. , Makani, Samir, Maldonado, Fabien , Matrka, Laura , McWhorter, Andrew J., Meratı, Albert L., Mori, Matthew , O’Dell, Karla , Postma, Gregory N. , Reder, Lindsay , Richardson, Brent E. , Rickman, Otis B. , Rosen, Clark A. , Rutter, Michael J. , Sandhu, Guri, Schindler, Joshua S. , Schneider, Glenn Todd , Shah, Rupali N., Sikora, Andrew G. , Sinard, Robert J. , Smith, Marshall E. , Smith, Libby J. , Soliman, Ahmed M. S. , Sveinsdóttir, Sigríður, Veivers, David , Verma, Sunil P., Weissbrod, Philip A. , Wootten, Christopher T. , Shyr, Yu , Francis, David O. , Daele, Douglas J. Van , Chen, Sheau-Chiann , Cohen, Seth M , Hoffman, Henry T , Weissbrod, Philip A , Amin, Milan R , Bock, Jonathan M. , Clary, Matthew S. , Guardiani, Elizabeth , Hillel, Alexander T. , Lott, David G. , Netterville, James L. , Ongkasuwan, Julina , Rohde, Sarah L. , Rohlfing, Matthew L. , Weinberger, Paul , Gelbard, Alexander

Mayo Clinic

Otolaryngology–Head and Neck Surgery | January 19, 2023 | Volume: 168 | Issue: 6 | Pages: 1570-1575

10.1002/ohn.190 | PMID 36939627 Get It

Abstract The North American Airway Collaborative (NoAAC) previously published a 3‐year multi‐institutional prospective cohort study showing variation in treatment effectiveness between 3 primary surgical techniques for idiopathic subglottic stenosis (iSGS). In this report, we update these findings to include 5 years of data evaluating treatment effectiveness. Patients in the NoAAC cohort were re‐enrolled for 2 additional years and followed using the prespecified published protocol. Consistent with prior data, prospective observation of 487 iSGS patients for 5 years showed treatment effectiveness differed by modality. Cricotracheal resection maintained the lowest rate of recurrent operation (5%), followed by endoscopic resection with adjuvant medical therapy (30%) and endoscopic dilation (50%). These data support the initial observations and continue to provide value to providers and patients navigating longitudinal decision‐making. Level of evidence: 2—prospective cohort study.
Blast phase myeloproliferative neoplasm: Transplant to the rescue
Tefferi, Ayalew , Bacigalupo, Andrea

Mayo Clinic

American Journal of Hematology | January 19, 2023 | Volume: 98 | Issue: 4 | Pages: 553-555

10.1002/ajh.26849 | PMID 36655312 Get It

Treatment Strategies for Non-Small Cell Lung Cancer with Common EGFR Mutations: A Review of the History of EGFR TKIs Approval and Emerging Data
Marin‐Acevedo, Julian A. , Pellini, Bruna , Kimbrough, ErinMarie O. , Hicks, J. Kevin , Hicks, J Kevin , Pellini, Bruna , Chiappori, Alberto

Mayo Clinic

Cancers | January 19, 2023 | Volume: 15 | Issue: 3 | Pages: 629

10.3390/cancers15030629 | PMID 36765587 Get It

The development of targeted therapies over the past two decades has led to a dramatic change in the management of EGFR-mutant non-small cell lung cancer (NSCLC). While there are currently five approved EGFR tyrosine kinase inhibitors (TKIs) for treating EGFR-mutant NSCLC in the first-line setting, therapy selection after progression on EGFR TKIs remains complex. Multiple groups are investigating novel therapies and drug combinations to determine the optimal therapy and treatment sequence for these patients. In this review, we summarize the landmark trials and history of the approval of EGFR TKIs, their efficacy and tolerability, and the role of these therapies in patients with central nervous system metastasis. We also briefly discuss the mechanisms of resistance to EGFR TKIs, ongoing attempts to overcome resistance and improve outcomes, and finalize by offering treatment sequencing recommendations.
Comparing Tigertriever 13 to other thrombectomy devices for distal medium vessel occlusion: A systematic review and meta-analysis
Adusumilli, Gautam , Kobeissi, Hassan , Ghozy, Sherief , Brinjikji, Waleed , Kallmes, David F. , Heit, Jeremy J. , Kallmes, Kevin M , Kallmes, David F , Heit, Jeremy J , Ghozy, Sherief , Kobeissi, Hassan

Mayo Clinic

Interventional Neuroradiology | January 19, 2023 | Volume: 32 | Issue: 3 | Pages: 657-664

10.1177/15910199231152510 | PMID 36655307 Get It

Background There is limited evidence on the optimal endovascular strategy for treatment of distal medium-vessel occlusions (DMVO). The low-profile Tigertriever 13 stent-triever shows early promise as an adaptable device that can navigate the distal vasculature without increasing complication risk in DMVO. Methods Using Nested Knowledge, we screened literature for RCTs and cohort studies on the endovascular treatment of DMVO. The primary outcome was reperfusion success, as measured by thrombolysis in cerebral infarction (TICI) ≥ 2b and secondary outcomes included rate of symptomatic intracranial hemorrhage (sICH), mortality at 90 days, and modified Rankin scale (mRS) scores 0–2 at 90 days. A random-effects model was used to compute pooled prevalence rates and their corresponding 95% confidence intervals (CI). Results Eleven studies with 1402 patients, 167 patients treated by Tigertriever 13 and 1235 patients treated by other devices, were included in the meta-analysis. The rate of reperfusion success was similar in patients treated by Tigertriever 13 (83.2% [95% CI: 71.5–96.7%]) versus other devices (81.6% [95% CI: 75.3–88.4%], p > 0.05). The rate of sICH was also similar in patients treated by Tigertriever 13 (7.2% [95% CI: 4.1–12.5%]) versus other devices (6.9% [95% CI: 5.5–8.8%]). There was significant heterogeneity in the reporting of mortality and mRS. Conclusions Tigertriever 13 had similar rates of reperfusion success and sICH as other devices used for the treatment of DMVO. Heterogeneity in data element reporting prevented further analyses. Further studies evaluating Tigertriever 13 and other potential devices in DMVO should attempt to harmonize data element reporting.